|
|
楼主 |
发表于 2025-1-9 17:21:59
|
显示全部楼层
还统计少了，华西医院牵头是25项
" D1 K" Y# ^8 @5 A/ X: ^01.Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.% ]5 P3 a% i' z* b5 K: U; H
02.Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.- @& r2 g& ?; q' r
03.Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.
v! D% \, V: X) y$ r/ q- K04.The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.( v, s# Q0 z1 g2 ~- ?3 c0 s! Q
05.Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
4 r1 Y3 h( [; d( D" `3 ^06.Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
, m* T# E' R3 ?+ z* l$ ?07.Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.; C# O- ?; v# y2 h. O8 ?' n/ g5 D
08.Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.( ]8 }& o: j2 J: i1 {$ Z! p9 L; g
09.Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study." b! c' U9 q; ?; ^
10.Interpretable machine learning for prostate biopsy: Cohort study.' j5 l @& T3 L
11.Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.- ^6 q( d- Z' G+ ]! M8 k
12.Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
! R E! K& j9 V13.Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).' y% W/ v3 [# W! l( W) ]! z
14.A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).+ q9 @" l5 a4 u( y
15.VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.
" Q5 @# g9 {& R1 I9 ]% x* c16.Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.6 k+ q1 V# V c! M- }* A- Q
17.Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
* q' X$ T& ~; ]8 ?18.Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift. w# m6 H( @7 O }
19.Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.- ]) ~5 L; g' g
20.The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.) y, p7 }9 ^$ ^3 c1 ~, |
21.Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.4 b/ O( c( M( \+ z: j, m
22.Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.
3 F. h0 T8 k$ f' O. \( x, K23.Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.7 i: b9 t7 H3 e2 O- {
24.The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
( ?" ~# j. O0 X; \5 k# W25.Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.
. h5 g2 F/ C" }5 q; d |
|
发表于 2025-1-9 15:59:44
发表于 2025-1-9 17:01:32
看年内重离子质子医院投运后，能否发起追赶
